Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology News
Share

VBL Therapeutics won an ILS8.75 (approximately $2.5 million) grant from the Israel Innovation Authority to support continued clinical development of the firm’s lead Phase III-stage gene therapy ofranergene obadenovec (VB-111). The antiangiogenic candidate is being evaluated in a pivotal Phase III GLOBE study in patients with recurrent glioblastoma...

In gene editing, the kindest cut may be no cut at all. This possibility was explored by researchers working with peptide nucleic acids (PNAs), synthetic molecules that combine a protein-like backbone with the nucleobases found in DNA and RNA. When deployed by researchers based at Carnegie Mellon University and Yale University, PNAs succeeded in...

Success in Humanizing Mice Has Inspired Similar Efforts in Rats, Pigs, and Other Animals Ian Clift, Ph.D. One of the major roadblocks to curing cancer is modeling the complexities of the disease; thus, increasingly refined models of the disease are necessary. The result has been a sizable increase in the number of genetically engineered and, more...

The FDA approved Celltrion’s Inflectra™ (biosimilar infliximab) across all eligible indications of the reference product, Janssen Biotech’s Remicade® (infliximab). Inflectra is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U.S. Hospira, now a Pfizer company, entered into...

In June, South Korea-based Green Cross Biotherapeutics broke ground on the nation’s first intravenous immunoglobulin (IVIG) and albumin manufacturing plant, a C$315 million facility that will employ 200 scientists, engineers, microbiologists, chemical ...

In the current study, the researchers evaluated their new method in biological samples (blood, stool, and nasal secretions ... but can cause severe infections in some patients. After assessing all of the data from the study groups the number of viruses ...

Scientists say both LUK-PV and LUK-ED are leukotoxins that target and poison the white blood cells meant to fight the bacterial infection, but LUK-PV is only secreted by community-acquired MRSA, or methicillin-resistant S. aureus. According to study senior ...